Clinical Trials Logo

Marginal Ulcer clinical trials

View clinical trials related to Marginal Ulcer.

Filter by:
  • None
  • Page 1

NCT ID: NCT05799105 Recruiting - Marginal Ulcer Clinical Trials

OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers

OPEN-IT
Start date: March 14, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to identify the most effective way to take acid-blocking medications to treat stomach ulcers in patients who have undergone gastric bypass surgery. The main questions it aims to answer are: - is taking an acid-blocking medication by opening the capsule and only taking the contents of the capsule (open-capsule) more or less effective than taking the capsule as a whole (intact-capsule) for treating ulcers in patients who have a history of gastric bypass surgery? - does taking the open versus intact medication decrease the number of procedures and complications from untreated ulcers? Participants with ulcers will be instructed to take acid-blocking medications (called proton-pump inhibitors) either by opening the capsule and taking only the contents or by taking the capsule whole. These medications are the gold standard for treatment of stomach ulcers. Participants will be asked to undergo an upper endoscopy (EGD) every 3 months to monitor the healing of the ulcers. Researchers will compare how quickly the ulcers heal depending on which way the medications are taken (opened up or as a whole).

NCT ID: NCT03163680 Completed - Clinical trials for Peptic Ulcer Hemorrhage

Efficacy of Low Dose of Proton Pump Inhibitor in Treatment Bleeding Ulcers

Start date: January 2012
Phase:
Study type: Observational

Determining the efficacy of low dose of PPI in management acute peptic ulcer bleeding

NCT ID: NCT03123835 Enrolling by invitation - Achalasia Clinical Trials

Outcome Analysis of POEM and Endoluminal Therapies

Start date: March 2016
Phase: N/A
Study type: Interventional

Evaluation of current and newly developed endoluminal therapies in the management of Upper and Lower GI conditions.

NCT ID: NCT02724150 Withdrawn - Clinical trials for Peptic Ulcer Hemorrhage

Comparison of Low Against High Regimen of Proton Pump Inhibitors for Treatment of Acute Peptic Ulcer Bleeding

Start date: December 1, 2017
Phase: Phase 4
Study type: Interventional

Evaluate the efficacy of Two different regimens of proton pump inhibitors High against Low in the management of acute peptic ulcer bleeding

NCT ID: NCT01041196 Completed - Marginal Ulcer Clinical Trials

Perforated Marginal Ulcer After Gastric Bypass

PerforatedMU
Start date: January 2009
Phase: N/A
Study type: Observational

A common late complication after gastric bypass surgery is marginal ulceration that is defined as ulcers at the margins of the gastrojejunostomy, mostly on the jejunal side. Most marginal ulcers respond to medical therapy and complicated or complex ulcer disease warrants operative intervention; specifically, perforated, penetrated, obstructing, bleeding and intractable marginal ulcers require surgical intervention. Diverse operative strategies for addressing perforated marginal ulcers after gastric bypass have been described including I) Omental (Graham) patch repair, II) Revision of gastrojejunostomy, III) Irrigation and drainage, IV) any previous procedure with truncal vagotomy, V) Esophagojejunostomy, and VI) Reversal. We formally analyze our experience with the laparoscopic resection and repair of acutely perforated marginal ulcers after Roux-en-Y gastric bypass (RYGB), with or without concomitant resolution of technical risk factors for marginal ulceration.

NCT ID: NCT01041079 Completed - Marginal Ulcer Clinical Trials

Chronic Marginal Ulcers After Gastric Bypass

ChronicMU
Start date: December 2008
Phase: N/A
Study type: Observational

The purpose of this study is to determine the feasibility, safety, and efficacy of revision gastroplasty along with other adjunct procedures in the treatment of intractable / chronic marginal ulcers after Roux-en-Y gastric bypass. A secondary aim is the identification of good and poor outcome predictors after revisional strategies for intractable or chronic marginal ulcer.